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Abstract
Background: Vitamin D is a pleiotropic hormone important for the recovery of organ systems after critical illness.
Recent observational studies have suggested that three out of every four children are vitamin D deficient following
cardiac surgery, with inadequate preoperative intake and surgical losses playing important contributory roles.
Observed associations between postoperative levels, cardiovascular dysfunction and clinical course suggest that
perioperative optimization of vitamin D status could improve outcome. With this two-arm, parallel, double blind,
randomized controlled trial (RCT), we aim to compare immediate postoperative vitamin D status in children
requiring cardiopulmonary bypass for congenital heart disease who receive preoperative daily high dose vitamin
D supplementation (high-dose arm) with those who receive usual intake (low-dose arm).
Methods/Design: Eligibility requirements include age (>36 weeks, <18 years) and a congenital heart defect
requiring cardiopulmonary bypass surgical correction. Enrollment of 62 participants will take place at a single
Canadian tertiary care center over a period of 2 years. Children randomized to the high-dose group will receive
age-based dosing that was informed by the Institute of Medicine (IOM) daily tolerable upper intake level (<1 year
old = 1,600 IU/day, >1 year old = 2,400 IU/day). Children in the low-dose arm will receive usual care based on
IOM recommendations (<1 year old = 400 IU, >1 year old = 600 IU). The primary outcome measure is immediate
postoperative vitamin D status, using blood 25(OH)D.
Discussion: Maintaining adequate postoperative vitamin D levels following surgery could represent an effective
therapy to speed recovery following CHD surgery. The proposed research project will determine whether preoperative
supplementation with a dosing regimen based on the IOM recommended daily upper tolerable intake will prevent
postoperative vitamin-D deficiency in the majority of children. The results will then be used to inform the design of a
large international RCT exploring whether preoperative optimization of vitamin D status might improve short and
long-term outcomes in this vulnerable population.
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Background
Congenital heart disease (CHD) is a common condition
with an estimated prevalence of 1 per 100 in the general
population. A significant proportion of these pediatric
patients require one or more corrective surgeries over
their lifetime, collectively leading to 15,000 procedures
per year in North America [1]. Postoperatively, these pa-
tients suffer significant morbidities, which may include a
pronounced systemic inflammatory response, multiple
organ failure, electrolyte disturbances, arrhythmia, infec-
tion and endocrine imbalances [2–5]. Interventions that
prevent or modulate postoperative pathophysiology may
prevent illness, speed recovery, and decrease chronic
morbidity in this high-risk pediatric population.
Vitamin D status is well recognized as important to
calcium homeostasis and musculoskeletal health. The
importance of Vitamin D and its physiological effects
are well understood in the context of hypocalcemia [6, 7].
Briefly, as serum calcium falls, the parathyroid increases
parathyroid hormone (PTH) secretion leading to activa-
tion of vitamin-D through an inducible renal enzyme. The
inducible renal enzyme works to convert serum 25-
hydroxyvitamin D [25(OH)D] to 1,25 -dihydroxyvitamin
D [1,25(OH)2D] and this active metabolite circulates to
the bone, gut and kidneys to restore homeostasis. It is
now known that many cell types do not rely entirely on
kidney production and have enzymes capable of con-
verting 25(OH)D to its active form for both autocrine
or paracrine use. Circulating 25(OH)D is well accepted
as the best marker for evaluating vitamin D status in
the majority of health settings, including the general
ICU population [8, 9]. The generally accepted thresh-
olds for defining vitamin D sufficiency is 75 nmol/L,
with deficiency defined as below 50 nmol/L, and severe
deficiency at 25 to 30 nmol/L).
Increasingly, vitamin D is accepted as a pleiotropic
hormone important for the functioning of organ systems
central to critical illness pathophysiology, including elec-
trolyte homeostasis, cardiovascular health, inflammation
and innate immunity [10–12]. This has lead to the hy-
pothesis that its deficiency might represent a modifiable
risk factor for critical illness. A growing number of obser-
vational studies in adult cardiovascular and intensive care
populations have investigated this hypothesis, and these
studies have reported high vitamin D deficiency rates and
associations between hormone level and organ dysfunc-
tion, health resource utilization and mortality [11, 13–20].
Further, a single moderately sized, interventional study on
critically ill adults (VITdAL-ICU) suggests that rapid re-
pletion of vitamin D may improve outcomes [21]. This
trial randomized 475 critically ill adults to an initial enteral
540 000 IU cholecalciferol loading dose (followed by
monthly 90,000 IU) or placebo doses. In this study there
was a nonsignificant absolute risk reduction in hospital
mortality of in the vitamin D arm (7.0 %, P = 0.10). How-
ever, in the predefined subgroup of patients with vitamin
D levels below 30 nmol/L at baseline this absolute dif-
ference became larger and statistically significant
(−17.5 %, P = 0.01). Although, large pediatric observa-
tional studies have also documented high rates of vita-
min D deficiency and associations between hormone
levels and clinical course within the PICU [22, 23], a
high dose interventional vitamin D trial in the PICU
has yet to be undertaken [24].
Patients with CHD requiring surgery have been inves-
tigated as subgroups within large PICU studies and as
distinct populations [22, 25]. Analysis of the CHD pa-
tients enrolled in a large multicenter Canadian PICU
reported a 70 % deficiency rate and associations between
vitamin D level and clinical course [22]. Further, Graham
et al. confirmed these observations with a secondary
analysis of postoperative blood specimens, reporting not
only that 84 % of neonates with CHD were vitamin D
deficient postoperatively, but that lower levels were asso-
ciated with inotropic requirements [25]. In addition, in a
prospective longitudinal study, we calculated an 85 %
vitamin D deficiency rate in the CHD population imme-
diately following surgery, as well as an association between
deficiency and postoperative fluid and catecholamine re-
quirements [26]. Mechanistic studies determined the high
rate of vitamin D deficiency to be secondary to borderline
normal preoperative 25 hydroxyvitamin D (25OHD) levels
and an acute 40 % intraoperative decline due to cardiopul-
monary bypass (CPB), consistent with that described in an
adult CPB study [27]. In summary, the available data
suggest that most CHD patients are vitamin D deficient
following cardiac surgery and that the immediate post-
operative levels are associated with subsequent clinical
course.
A role for vitamin D in critical illness has biological
plausibility, as there are multiple mechanisms through
which deficiency could cause secondary pathophysiology.
Hypocalcemia is a common problem following CHD
repair (30 %) and calcium replacement is associated with
morbidity and mortality [5]. Adult and pediatric ICU
studies have shown that critically ill patients with hypo-
calcemia are more likely to have abnormalities of their
vitamin D axis, including low 25OHD, hypoparathyroid-
ism and/or renal dysfunction [28–30]. A role for vitamin
D in cardiac health can be found in case reports and
case series describing cardiomyopathy secondary to
isolated severe vitamin D deficiency [6, 31–33]. A recent
RCT of vitamin D supplementation in outpatient pediatric
congestive heart failure showed improved cardiac function
with a higher daily dose of vitamin D [34]. Additionally,
cardiac surgery with cardiopulmonary bypass uniformly
leads to a postoperative systemic inflammatory response
syndrome [35, 36]. There is good evidence that vitamin D
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metabolites play important immunomodulatory roles me-
diated through functional vitamin D receptors present on
all major immune cell types [37–39]. Vitamin D signal-
ing is also known to play a role in innate immunity,
such as in the production of cathelicidins [40–42].
Cathelicidins, important endogenous antimicrobial pep-
tides, provide protection against multiple viral and bac-
terial pathogens. Prevention of vitamin D deficiency
could decrease nosocomial infections among CHD pa-
tients through improved innate immunity.
The current body of knowledge suggests that optimi-
zation of vitamin D status prior to and following CHD
repair could improve clinical outcomes through reduced
inflammation, fewer nosocomial infections, improved
cardiac function, and faster postoperative rehabilitation
and physical functioning [11, 13–17, 43–45]. However,
before these findings can be translated into clinical prac-
tice, a number of unknowns must be addressed. For
instance, there have been no interventional studies es-
tablishing that prevention of postoperative vitamin D de-
ficiency improves clinical outcomes in CHD patients. In
addition, attempts to perform a large RCT would be pre-
mature because a dosing regimen that prevents postop-
erative vitamin D deficiency has not yet been identified.
Moreover, there have been no vitamin D dosing studies
or guidelines developed specific to the CHD population;
presently children with CHD receive the same advice re-
garding supplementation as healthy children [46]. Al-
though it is tempting to extrapolate recent safety data
from high dose vitamin D studies on healthy children to
the CHD population, this may be inappropriate. CHD
patients have unique metabolic demands, organ dysfunc-
tions, as well as known and unknown genetic abnormal-
ities that potentially make them more or less susceptible
to vitamin D [47–50]. To begin addressing these know-
ledge gaps, we have designed a pilot dose evaluation
randomized controlled trail (RCT) with the goal of
identifying a supplementation regimen that safely pre-
vents postoperative vitamin D deficiency in children re-
quiring cardiopulmonary bypass for CHD.
Objectives and hypotheses
Hypothesis
In pediatric patients requiring surgery for CHD, pre-
operative supplementation with a daily high dose vita-
min D regimen, modelled on the Institute of Medicine
(IOM) Tolerable Upper Intake Level (UL) [46], will sig-
nificantly reduce postoperative vitamin D deficiency,
when compared with usual care.
Study objectives
The primary and secondary objectives are as follows:
1. The primary objective is to perform a double-blind
RCT to determine whether the preoperative admin-
istration of a daily high dose of vitamin D, based on
the UL from IOM [46], compared with usual care,
results in a significant reduction in postoperative
vitamin D deficiency in a pediatric population with
CHD.
2. Secondary objectives
a. Determine whether the preoperative regimen of
daily high dose vitamin D, compared with usual
care, results in a greater number of vitamin D
related adverse events (hypercalcemia,
hypercalciuria).
b. Determine whether the preoperative regimen of
daily high dose vitamin D, compared with usual
care, improves established markers of vitamin D
axis functioning (active hormone levels, cardiac
function).
c. Determine the barriers and feasibility of
conducting a larger phase III RCT evaluating
whether vitamin D supplementation improves
clinical outcomes in children who require CHD
surgery (blinding, recruitment, and compliance).
Methods/Design
The Heart and Stroke Foundation of Canada is the
Sponsor for the trial. The study will be conducted in
accordance with the ethical principles guided by Tri-
Council Policy and the Declaration of Helsinki. The
protocol is approved by Health Canada (no objection
letter, Protocol #VitaminDinCHD-01) and the Children’s
Hospital of Eastern Ontario Research Ethics Board (REB
reference: 13/03E). The trial will comply with the princi-
ples of Good Clinical Practice and will be carried out in
accordance with applicable legislation and the Standard
Operating Procedures of the CHEO Research Institute.
The trial will be reported in line with the Consolidated
Standards of Reporting Trials (CONSORT) 2010 guide-
lines [51] and the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) checklist [52]
(Additional file 1). Protocol amendments will be commu-
nicated as necessary to those involved with the study. A
structured summary of the trial is provided in Table 1.
Study design
The trial is a single center, double blind, parallel, ran-
domized, controlled dose evaluation trial comparing the
efficacy and safety of two vitamin D dosing regimens in
the prevention of postoperative vitamin D deficiency in
children undergoing surgery for CHD.
Study population
Inclusion
Inclusion criteria are as follows:
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1. Between 36 weeks gestational age and 18 years
2. CHD requiring surgery within the next 12 months
3. CHD requiring surgical correction with
cardiopulmonary bypass (CBP)
Exclusion
Exclusion criteria are as follows:
1. Born at less than 32 weeks gestational age
2. Cardiac or gastrointestinal disease prevented enteral
feeds or drug administration prior to surgery
3. Confirmed or suspected William’s syndrome a
neurodevelopmental genetic disorder with
symptoms that include cardiovascular problems and
high blood calcium
4. Proposed surgery to take place at another center
(outside of CHEO)
Justification of eligibility criteria
In our previous study, CHD patients who did not receive
CPB had a minimal (<10 %) intraoperative drop in
25OHD. Although prevention of vitamin D deficiency is
important for these patients, they do not require pre-
operative elevation into the upper normal physiological
range. Very premature infants (<32 weeks) are at signifi-
cantly increased risk for nephrocalcinosis [53, 54]. CHD
patients with Williams syndrome have a genetic suscepti-
bility to hypercalcemia and current guidelines recommend
against any vitamin D supplementation [49, 55].
Study drug
Study drug distribution
Europharm will provide the study drug (vitamin D) in
the required concentrations, prepared in indistinguish-
able vials for blinding purposes. The study drug will be
Table 1 World Health Organization Trial Registration Data Set – Structured Summary
Data category Information
Primary registry, trial identifying # Clinicaltrials.gov Identifier - NCT01838447
Date of registration in primary registry April 11, 2013
Secondary indentifying numbers HICCUPS, VitaminDinCHD-01, 13/03E
Sources of monetary support Heart and Stroke Foundation of Canada Operating Grant, Children’s Hospital of Eastern
Ontario Research Institute
Primary sponsor Heart and Stroke Foundation of Canada
Secondary sponsor Children’s Hospital of Eastern Ontario Research Institute
Contact for public queries JDM, Pediatric Critical Care, Children’s Hospital of Eastern Ontario, Ottawa, Canada
Contact for scientific queries JDM, Pediatric Critical Care, Children’s Hospital of Eastern Ontario, Ottawa, Canada
Public title Prevention of vitamin D deficiency after congenital heart disease surgery:
a dose evaluation trial
Scientific title Prevention of vitamin D deficiency in children following cardiac surgery:
a study protocol
for a randomized dose evaluation trial
Country of recruitment Canada, single academic center
Health problem under investigation Prevention of vitamin D deficiency after congenital heart disease surgery
Key inclusion and exclusion criteria Ages eligible for study: Corrected gestational age >36 weeks and <18 years.
Inclusion criteria: has CHD requiring surgical correction with cardiopulmonary bypass
within 12 months
Exclusion criteria: born at <32 weeks gestational age; cardiac or gastrointestinal
disease preventing enteral feeds or drug administration prior to surgery; has
confirmed or suspected Williams syndrome; proposed surgery to take place at
another center
Study type Single center, double blind, parallel, randomized, controlled dose evaluation trial
Date of first enrollment June 2013
Target sample size 62
Recruitment status Recruiting as of June 2015
Primary outcome Using immediate postoperative vitamin D status, (that is blood 25OHD) we will
determine whether the preoperative administration vitamin D compared with
usual care results in a significant reduction in postoperative vitamin D deficiency
in a pediatric population with CHD.
Key secondary outcomes Vitamin D related adverse events (that is hypercalcemia, hypercalciuria); vitamin D
axis functioning (active hormone, cardiac function); study feasibility
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analyzed as per Health Canada regulations. The phar-
macy will administer the study drug according to
randomization, participant age, and whether the patient
is being breast-fed or formula fed. Infants with CHD
assigned to the usual care arm will be given either a
placebo (0 IU/mL) solution if they are receiving vitamin D
as part of formula, or they will be given a 400 IU/mL solu-
tion if they are breast-fed.
Proposed supplement doses (interventions) to be tested
and rationale
Treatment groups
The doses for evaluation have been modelled on the two
age-specific intake levels recommended by the IOM [46]
(Table 2).
Further details on the study drug: (1) Isoform - chole-
calciferol (D3), (2) Route – Enteral, (3) Form – Solution
(4) Frequency – Daily, (5) Duration – from time of CHD
diagnosis to day of operation (started no more than 6
months prior to surgery date). Euro-pharm has agreed
to provide the study drug in 50-mL vials with the following
concentrations to achieve blinding: placebo, 400 IU/mL,
600 IU/mL, 1200 IU/mL, 1600 IU/mL, and 2400 IU/mL.
The high-dose group is based on the age-specific UL.
These doses were chosen to elevate 25OHD well above
50 nmol/L, while minimizing risk of vitamin D toxicity
(for example, hypercalcemia or hypercalciuria). Patients
under 1 year of age will receive 1,600 IU/day, whereas
those over 1 year of age will receive 2,400 IU/day.
Infants under 6 months of age in the high-dose group
will receive 600 IU/day more than the UL from IOM,
whereas those between 6 and 12 months will receive 100
IU/day more than the UL.
The usual care group will receive Adequate Intake
(AI) for infants and Recommended Dietary Allowance
(RDA) for children over 1 year old (<1 year old, 400
IU; >1 year old, 600 IU/day). These doses were chosen
by IOM to achieve blood 25OHD levels above 50
nmol/L in the vast majority of the healthy population.
Rationale for inclusion of the usual care arm
Given that children with CHD receive the same vita-
min D supplementation advice as healthy children (by
default), it is tempting to conclude that usual care
dosing will be insufficient to prevent vitamin D defi-
ciency. Unfortunately, this conclusion may be wrong
for the following reasons: (i) only 50 % of previous
study participants indicated daily vitamin D intake at
or above 400 IU [22], (ii) compliance with vitamin D
supplementation may be poor without motivation
(research studies, vitamin D-related disease), (iii) there
is often uncertainty about vitamin D intake by care-
givers, and (iv) recommendations for usual care
recently increased to 600 IU for children above 1 year
old [46]. Given potential safety concerns regarding
high doses of vitamin D in diseased population, it
would be appropriate to properly evaluate the efficacy
of usual care under ideal circumstances.
In addition, it is important to assess the baseline risk
for vitamin D-related adverse events in CHD patients
receiving the usual (standard of care) dosing. Although
studies on healthy children have not identified adverse
events (for example, hypercalcemia or hypercalciuria)
with doses at and slightly above the IOM tolerable upper
intake level [56, 57], diseased populations including
those with CHD may be predisposed at lower 25OHD
levels.
Rationale for preoperative daily enteral approach
Our previous prospective study demonstrated that
post-CHD surgery, vitamin D deficiency occurs due to
borderline normal preoperative values and a consistent
CPB-induced intraoperative decline [26]. As there is no
intravenous form of cholecalciferol, or 25OHD, main-
tenance of appropriate postoperative levels will require
elevation of preoperative levels into the high normal
range using enteral supplementation. Two basic ap-
proaches for enteral restoration and maintenance of vita-
min D stores have been described. First, representing
Table 2 Vitamin D supplementation strategy
A: Breastfed infant or over 12 months of age
Age Group Volume Standard Dose Group High Dose Group
mL IU per day Vial Concentration IU per day Vial Concentration
0 to 1 year 1 400 IU 400 IU/mL 1600 IU 1600 IU/mL
1 to 17 years 1 600 IU 600 IU/mL 2400 IU 2400 IU/mL
B: Formula fed and under 12 months of age
Age Group Volume Standard Dose Group High Dose Group
mL IU per day Vial Concentration IU per day Vial Concentration
0 to 1 year 1 Nonea Placebo, 0 IU/mL 1200 IUa 1200 IU/mL
aDoes not include the vitamin D intake from formula (400 IU/day)
bWe will not increase vitamin D levels in those children who turn 1 year old after initiating the study drug
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usual care, is the daily consumption of a relatively low
dose of cholecalciferol (400 to 4,000 IU/day). The second
option is a single or divided megadose of vitamin D
(100,000 to 600,000 IU) given intermittently throughout
the year [58, 59]. As safety concerns regarding the mega-
dose approach in children have not been adequately ad-
dressed, we have chosen to evaluate regimens based on
daily consumption [60].
Anticipated duration of study drug and perioperative
25OHD levels
Duration of study drug
Vitamin D supplementation is generally initiated within
a week of birth, so the duration of preoperative therapy
would be from birth (or diagnosis of CHD) to the time
of surgery. Timing of surgery is very dependent on the type
of CHD lesion. Consistent with the literature, our recent
observational study of perioperative vitamin D status dem-
onstrated 8 months as the median age at surgery, with 2.4
months being the 25th percentile. Based on these findings,
we anticipate that it should be possible for 75 to 80 % of
patients to receive study drug for more than 2 months (the
time required to achieve a new 25OHD steady state with
high dose daily supplementation). Whether this duration of
study drug can actually be achieved preoperatively and the
25OHD levels achieved will be reported as part of the pilot
study.
Perioperative 25OHD levels
Given the 40 % intraoperative decline, preoperative
levels above 90 nmol/L will be required to maintain
postoperative levels above 50 nmol/L (the value at which
sufficient substrate to synthesize the active metabolite is
available). The ability of certain vitamin D intake levels
to achieve this preoperative value can be inferred from
recently completed dosing studies on healthy children
level [56, 57]. These studies have shown that usual care
dosing for 2 to 3 months will achieve preoperative levels
of 90 nmol/L in only 40–50 %. In contrast, studies
evaluating doses approximating our higher daily intake
level (1600 IU/day) achieved mean 25OHD levels of 130
to 150 nmol/L, suggesting that 80 % of CHD patients
could achieve preoperative levels of 90 nmol/L or above.
Subject recruitment
Potentially eligible study participants will be identified in
the ambulatory clinics (cardiology, cardiovascular) or
inpatient wards (including pediatric intensive care and
neonatal intensive care unit) by a member of the study
staff. A research coordinator will provide study informa-
tion and obtain informed consent as well as applicable
assent from each participant (Additional file 2). Study
staff will provide support to participants and encourage
adherence to intervention protocols.
Randomization, blinding and stratification procedures
We will use a computer-generated randomization se-
quence. Only the CHEO pharmacy will have access to
the randomization sequence and will be responsible
for participant randomization and allocation. Only the
pharmacist will know the identity of the study drug
administered to specific patients. Given the expected
recruitment (two to three per month) and potential
impact of season on 25OHD, randomization will be
performed in permuted blocks (four within each
stratum). We will blind patients, families, investigators,
hospital staff, and research personnel to treatment arm.
Blinding was considered necessary to avoid (i) families
altering the outpatient dose and (ii) a number of sec-
ondary outcome measures are that are potentially sub-
jective (echocardiography, timing of extubation, need
for fluids or catecholamine infusion). Within each age
group, the two interventions will be indistinguishable
(vial, volume, color, taste, consistency and smell).
Participants will be stratified into whether or not they
are expected to receive at least 8 weeks of study drug
prior to surgery. This stratification should guarantee that
an equal number of CHD patients who will not receive 8
weeks of oral dosing end up in both the high and low
dose arms. We will further stratify by age (under or over
1 year of age).
Co-interventions
We will not protocolize postoperative co-interventions as
the study is single center and CHEO has standardized
approaches to the common postoperative complications
and adverse events (for example, hypocalcemia, junctional
ectopic tachycardia, necrotizing enterocolitis constipation,
sedation, catecholamine administration, etcetera). As the
study is blinded, protocolization of co-interventions is less
relevant and differences should relate to random chance
or drug effects.
Diagnostic and clinical outcome measures
Blood 25OHD
The primary objective will be evaluated using immediate
postoperative blood 25OHD concentrations (collected
on the day of ICU admission) with a level lower than 50
nmol/L used to define deficiency [61, 62]. This is a well-
established cut-off based on (i) the knowledge that the
parathyroid and renal organs need to compensate for
25OHD levels below 50 nmol/L and (ii) clinical studies
that have shown increased risk of bone, cardiovascular,
immune and other disease entities once concentrations
fall below this level. The 25OHD will be determined
using a LC-MS/MS assay from a laboratory participating
in the Vitamin D External Quality Assessment Scheme
(DEQAS) [22, 63].
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Vitamin D-related adverse events
We will report, by intervention, on the occurrence of
clinically significant adverse events. However, a measur-
able difference in clinically significant adverse events
between the high dose and usual care arms of the study
is unlikely. Therefore, to enhance our ability to evaluate
for potential toxicity, we will use two well-accepted sur-
rogate outcome measures:
1. Hypercalcemia: This will be defined as an ionized
calcium level above 1.40 mmol/L (or above 1.45
mmol/L for children under 8 weeks) (Table 3). We
will evaluate for hypercalcemia in blood collected
immediately before surgery and throughout the
postoperative course (measurements are a
standard of care, and any single episode of
hypercalcemia not related to parenteral
administration of calcium will be considered an
adverse event) [64].
2. Hypercalciuria - We will identify hypercalciuria
using calcium:creatinine ratios defined using age-
specific norms and thresholds (Table 3) [64–66].
Measurements will be performed on urine collected
in the operating room immediately prior to surgery
and on the first postoperative day.
Vitamin D axis function
We will evaluate vitamin D axis function through changes
in 1,25(OH)2D [22] levels from blood collected at specified
times following surgery. Based on our previous work, we
anticipate a 40 % intra-operative decline in 1,25(OH)2D
levels [8] and some children will experience a transient
decline in 1,25(OH)2D levels into the deficient range (<50
pmol/L). Given adequate 25OHD levels and an otherwise
properly functioning vitamin D axis, we anticipate
restoration (or maintenance) of active hormone levels into
the normal range within 12 hours of surgery. Impaired vita-
min D axis function will be defined as an inability to main-
tain active hormone levels in the normal range at any point
from blood work collected after the first postoperative day.
Organ function and ICU outcome measures
Postoperative cardiovascular and immune function will
be measured and compared between the two groups.
Cathelicidin levels, an endogenous antimicrobial peptide,
will be used as a surrogate measure of innate immune
function [40, 41, 67]. Clinically relevant measures of
cardiac organ function including echocardiograms (for
example, ejection fraction), inotrope requirements (for
example, vasopressor need or maximum inotrope score)
and fluid resuscitation (positive fluid balance in first 48
hours). Further, we will also evaluate standard PICU
clinical outcome measures including time to extubation
and PICU and hospital lengths of stay.
Phase III study feasibility
We will determine the feasibility of a subsequent multi-
center large interventional study through an evaluation
of study recruitment rate, proportion of protocol viola-
tions, proportion of adequate allocation concealment
and blinding, proportion of study drug compliance, and
proportion of study drop out.
Study procedures
A summary of study procedures, biological sample collec-
tion and metabolite measurements has been provided as a
flow diagram (Fig. 1) and the biochemical measurements
on research specimens are summarized in Table 4.
Prior to initiation of study drug
Urine - After consent is obtained and the study partici-
pant is waiting for the pharmacy to prepare the study
drug, we will gather a urine sample for determination
of calcium:creatinine ratios. Where developmentally
appropriate, the participants will be asked to provide
urine into a container. Urine bags will be placed on
younger children. If the child is unable to provide a
urine sample during the time it takes to fill the study
drug prescription, the participant will be provided with
a container or urine bag and asked to provide an out-
patient urine sample.
Blood - Neonates and other study participants requir-
ing surgery within 2 months of diagnosis and enroll-
ment will have 0.5 to 1 mL of blood collected prior to
Table 3 Safety thresholds for ionized calcium, total corrected
calcium and elevated calcium-creatinine ratio
Table 3A: Age specific thresholds for pH corrected ionized calcium levels
Age (months) 95th % (mmol/L)
<2 1.45
>2 1.4




Table 3C: Age specific thresholds for elevated calcium-creatinine ratio
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(or within 2 days) of starting the study supplement for
determination of 25OHD. Where possible, unused or
discarded blood will be obtained from the laboratory
[68]. If unused blood is not available, research blood
will be collected at the time of clinically indicated blood
work, or not at all. These patients will not have blood
collected for research purposes again until they are
taken to the operating room.
* Note - We will request initiation samples but chil-
dren will still be enrolled if these samples cannot be
collected or the families do not want these procedures.
During period of study drug administration
All outpatient participants will have blood collected at
the time of standard presurgical blood work (2 to 3
weeks prior to surgery) for both 25OHD and ionized
Fig. 1 Flow chart of study-related procedures and measurements. Patients and/or caregiver may decline initiation blood work and urine samples and
still participate. Postoperatively, urine will only be collected at PICU admission if it was not collected in the operating room. Participants with isolated
postoperative hypercalciuria will only have renal ultrasound at the request of nephrology. CHD, congenital heart disease; PICU, Pediatric Intensive Care
Unit; POD, postoperative day
McNally et al. Trials  (2015) 16:402 Page 8 of 14
calcium. These samples are collected to ensure that
patients do not go for surgery with potentially toxic levels
of vitamin D. The safety officer will review the ionized
calcium level on the patients chart, and follow up if re-
quired, as per the safety measures outlined in the sections
below. For those participants who will receive the study
drug for more than 6 months, we will measure 25OHD
and calcium, and they will also have additional blood work
to ensure that potentially toxic levels are not maintained
for long periods prior to surgery. The timing of this blood
work will not be specified and will occur as part of clinic-
ally indicated blood work during regularly scheduled clinic
appointments
Intraoperative biological samples and measurements
Blood - All study participants will have 2 mL of blood
collected in the operating room following anesthesia and
intubation, but prior to skin incision and initiation of
cardiopulmonary bypass. Preoperative ionized calcium
will be determined. Remaining sample will be aliquoted
and stored at -80 °C for determination of 25OHD at the
end of the study.
Urine - All study participants will have urine collected
after insertion of the urinary catheter and the calcium:-
creatinine ratio will be determined. Study results will not
appear on the patient hospital chart, but will be labeled
with the study ID number and forwarded to the study
investigator and safety officer for review.
Postoperative biological samples and other study
measurements
Blood - All study participants will have 2 mL of blood
collected following separation from cardiopulmonary
bypass (at admission to PICU). Table 4 shows the bio-
markers to be measured. Further, study participants will
have 2 mL of blood collected on postoperative days 1, 3,
5 and 10 in the PICU. Samples will be collected from
arterial or central venous catheters at the time of clinic-
ally indicated blood work. If these catheters have been
removed, blood will be collected at the time of clinically
indicated venipuncture. If patients are discharged to the
ward before the day 10 research sample is collected, a
discharge sample will be collected at the time of
discharge and no further research blood will be gathered.
To limit the volume of research blood collected, neo-
nates will only have 1 mL of blood collected postopera-
tively on days 3, 5, and 10.
Urine - All study participants will have urine collected
from the urinary catheter on the first postoperative
day. Calcium and creatinine concentrations will be
determined.
Echocardiography - A comprehensive exam will be
performed immediately postoperatively (standard of care)
and on the first postoperative day by a trained technician
or pediatric cardiologist. Between-group comparisons will
evaluate for differences in left-ventricular in (LV) end-
diastolic diameter, LV end-systolic diameter, and LV ejec-
tion fraction [34].
Case report form
All trial information will be stored in a secure elec-
tronic database to maintain confidentiality. Data entry
methods are in place to promote data quality. In
addition, protocol deviations, including discontinuation
of study participation, will be recorded. The case report
form will be developed using REDCap [69]. Research
Table 4 Biochemical measurements on research specimens
Sample Timepoint
Pre-treatmenta During study drug administrationb Preoperativec Operating room prior to surgery Postoperative
Blood Vitamin Dd Vitamin Dd Vitamin Dd Vitamin Dd Vitamin Dd
Ionized calcium Ionized calcium Ionized calcium Ionized calcium
VDBP VDBP
PTH PTH
Immune function Immune function
(for example, cathelicidin) (for example, cathelicidin)
Immune activity Immune activity
(for example, cytokines) (for example, cytokines)
Urine Calcium to - - Calcium to Calcium to
Creatinine ratio Creatinine ratio Creatinine ratio
aneonates, or < 2 months of supplement anticipated
bany patient who receives > 6 months of supplement
call outpatients who receive > 2 months of supplement
d25OHD will be measured to indicate vitamin D status. The 25OHD level determined at the time of standard preoperative blood work, for safety purposes, will be
ordered through the laboratory. The intraoperative and postoperative 25OHD measurements will be determined, using LC-MS/MS technology that adheres to and
meets the standards of the Vitamin D External Quality Assessment Scheme
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Electronic Data Capture is a secure web application for
building and managing online surveys and databases.
The following data will be entered electronically:
1. Questionnaire - On the day of surgery the research
coordinator will collect the participant dairies and
unused study supplement. The patient diaries will
contain information on which days the patient was
given the study drug, why not, and whether there
were difficulties. Information will also be collected
on prescribed medications, nutrition, additional
supplement use, and symptoms associated with
vitamin D intoxication (for example, constipation or
abdominal discomfort).
2. Operative details - The research assistant will extract
detailed operative information, including the
following: cardiac lesion type, surgery performed,
RACHS score [70], total fluid intake and output,
blood product and fluid administration and loss,
hypothermia, need for deep hypothermic circulatory
arrest (duration), aortic cross clamp times, CPB
circuit volumes, CPB circuit constituents, CPB time,
occurrence of intraoperative hyper or hypocalcemia,
administration of parenteral calcium, need for
catecholamines following separation from CPB, and
occurrence of intraoperative arrhythmias.
3. PICU course - Clinically relevant information on
clinical course and organ dysfunction will be
collected, including: death, ECMO, PRISM illness
severity [71], cardiovascular dysfunction (fluid bolus
requirements, inotrope/catecholamine use,
arrhythmia), renal dysfunction (urine output,
creatinine measurements, need for dialysis),
hypocalcemia and calcium administration, duration
of mechanical ventilation and duration of PICU stay.
Statistical analysis
Sample size justification
Based on our observational studies and findings from re-
cent dose evaluation studies on healthy children, we esti-
mate that no more than 40 % of the usual care arm will
have postoperative 25OHD levels above 50 nmol/L.
Based on the 25OHD levels achieved with 1600 IU/day
in recent studies on approximate IOM high dose in
healthy children, we anticipate that 80 % of the high
dose arm will have postoperative levels above 50 nmol/L.
Therefore group sample sizes of 28 in both treatment
arms will be required to achieve 80 % power to detect an
absolute difference between the group proportions of 0.40.
The test statistic used is the two-sided Fisher’s exact test
and the significance level of the test was targeted at 0.05.
Assuming a 10 % drop-out rate, approximately 62 patients
(total) will need to be recruited.
Comments on power for evaluating vitamin D-related
adverse outcomes
Hypercalcemia - Our previous observational study (n =
58) identified no cases of preoperative or immediate
postoperative hypercalcemia [26]. With a baseline rate in
the usual care arm between 0 and 10 %, our sample size
would be sufficient to show a statistically significant
absolute difference between groups if the rate in the
high dose arm exceeded 30 %.
Hypercalciuria - Information on baseline rates of hy-
percalciuria prior to or following cardiac surgery with
usual care vitamin D intake is not available. The pro-
posed sample size would be sufficient to demonstrate a
35 % absolute difference in proportions if the baseline
pre- or postoperative rates are up to 20 %.
Statistical procedures
The analyses will be conducted using SAS software (Copy-
right SAS Institute Inc., Cary, NC, USA) and a P value less
than 0.05 will be considered statistically significant.
Descriptive statistics
Treatment groups will be described and compared using
(i) means with standard deviations or medians with
inter-quartile range values for continuous variables or
(ii) frequencies with percentages for categorical variables.
Statistically significant differences will be determined
using Chi-square and Fisher’s exact tests for categorical
variables, and t-tests or nonparametric tests (for example,
Wilcoxon) for continuous variables, as appropriate.
Primary outcome
The primary analytical approach will be to evaluate all
randomized patients in an intention to treat analysis.
Differences in the primary outcome measure, proportion
with 25OHD <50 nmol/L, between the treatment groups
will be evaluated using the Fisher’s exact test. Logistic
regression analysis will be used if important variables are
unevenly distributed between groups. We anticipate
minimal missing data because more than 95 % of partici-
pants from the recently completed observational study
had an immediate postoperative sample [26].
Secondary outcomes
Secondary analyses will be evaluated between groups
based on data type. Outcome measures that are continu-
ous will be evaluated using the t-test, Wilcoxon sign
rank test (where appropriate) or through linear regres-
sion analysis if important variables are not evenly
distributed between groups. Binary secondary outcome
measures (for example, hypercalcemia, hypercalciuria)
will be compared between the two treatment groups
using Fisher’s exact or Chi-square. For the analysis of out-
comes measures that represent time to event (for example,
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restoration of 1,25OH2D levels to normal range, time to
extubation, and PICU length of stay/discharge), we will
apply the log rank test. If randomization does not lead to
equal distribution of important variables (for example,
weight) the analysis will be expanded to multiple regression
modeling (for example, logistic, linear, Cox proportional
hazard).
Subgroup analysis
The well-known pharmacology of enteral vitamin D
dosing shows that up to 2 months of regular daily intake
is required to build body stores and achieve steady state
blood levels of vitamin D. Consequently, neonates or
other infants enrolled into the study who receive surgery
within two months of birth or CHD diagnosis will be
analyzed separately. Within this subgroup analysis, the
primary objective remains reporting of the proportions
(in the usual care and high dose groups) that are vitamin
D deficient postoperatively. However, given that these
participants will receive study drug for a very short
period, we anticipate that the proportion with 25OHD
levels above 50 nmol/L will remain low in the high dose
group. Our program goal at this stage is to identify a
dosing regimen that prevents postoperative vitamin D
deficiency in 75 % of CHD patients. Given this goal, and
an estimated prevalence of 25 % we would need 12 neo-
nates (or children who receive <2 months) to generate a
confidence interval that excludes 75 %.
Feasibility—Most neonates with CHD who require
cardiac surgery within the first few weeks of life have
serious cardiac lesions that can limit enteral nutrition
and medication delivery. Anticipating that most of these
patients will not significantly elevate 25OHD levels with
daily enteral intake at IOM high dose, this study will
provide important information on the willingness of
health care providers to provide enteral study drug. This
information will allow us to consider alternative dosing
regimens for future studies based on single or divided
doses representing one or more months worth of daily
dosing (for example, 5 to 10,000 IU/kg). Only those
children completing the entire study protocol will be
included in analyses.
Data and safety monitoring
In order to assess possible changes in risk/benefit ratio to
study subjects and to obtain independent oversight of study
conduct, an external Data and Safety Monitoring Board
(DSMB) will be established to oversee the progress of the
study. The DSMB will be composed of representatives from
statistics, nephrology and endocrinology. External DSMB
study reviews will be conducted after half of the partici-
pants (n = 30) have completed all study procedures. The
DSMB will review and monitor the study procedures and
potential risks with a focus primarily on safety. Serious Ad-
verse Events (SAEs) will be reviewed by the DSMB mem-
bers in order to determine whether additional safety
measures should be initiated. There are no predefined cri-
teria for stopping the study, although the DSMB may rec-
ommend changing study drug concentration or stopping
the study based on SAE or 25OHD data. If there are signifi-
cant deviations from major study assumptions, the DSMB
or study investigators may choose to evaluate 25OHD
levels and stop the study early.
The principal investigator and his co investigators will
be responsible for maintaining and assessing subject
safety in the study, monitoring the presence and severity
of adverse events, and monitoring compliance with study
drug use. Information on adverse events will be obtained
by laboratory findings, including 25OHD, ionized cal-
cium and urine calcium:creatinine levels.
Safety measures and clinically relevant research findings
A flow diagram depicts the safety measures in place and
response to clinically relevant research findings for indi-
vidual study participants (Additional file 3). A standard
operating procedure has been developed for adherence
to the following safety measures.
To avoid vitamin D overdose, hypercalcemia and side
effects, we have selected a supplement level recently
proven to be safe in healthy children and will target the
period of high-dose supplementation to 6 months and
no more than 12 months. Study participants with
elevated blood calcium and/or vitamin D levels will be
identified and contacted by the safety officer. For
25OHD, although 500 nmol/L is generally considered
the definitive acute toxicity threshold, we have chosen to
intervene with 25OHD levels above 200 nmol/L as this
value is supraphysiological and exceeds our study goal.
The following details the actions that will be taken with
abnormal values:
1. For 25OHD above 200 nmol/L with evidence
of hypercalcemia (vitamin D toxicity),
discontinue study drug immediately, repeat
the values (fasting), and refer to
endocrinology.
2. For 25OHD above 200 nmol/L without
hypercalcemia, the study drug will be reduced
by 50 %; (c) For 25OHD above 250 nmol/L, without
hypercalcemia: study drug will be discontinued.
3. For hypercalcemia with 25OHD under 200 nmol/L,
repeat the bloodwork (fasting) and refer to
endocrinology.
Both postoperative hypo- and hypercalcemia will be
managed by the clinical team as required. Study
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participants with persistently elevated blood calcium levels
(for more than 2 days, not explained by intravenous
calcium administration) will be referred to endocrinology
(Additional file 3).
As prolonged exposure to hypercalciuria (>3 months)
could theoretically cause nephrocalcinosis, we will have
ultrasounds performed prior to hospital discharge on all
patients with elevated immediate preoperative urine
calcium to creatinine ratios. Any study participant with
nephrocalcinosis will be referred to the nephrology service
for further assessment.
Participants that have study drug discontinued or de-
creased will be retained in the study, have perioperative
biological samples collected as outlined, and will be in-
cluded in the analysis using intention to treat
methodology.
Discussion
Research by our group and others has documented not
only that 4 out of every 5 CHD patients have inadequate
blood levels of vitamin D following surgery, but an associ-
ation between immediate postoperative hormone levels and
clinical course [22, 25, 26]. Altogether, these findings and
similar results in adult critical care and CHD surgery
populations, suggest that optimization of vitamin D status
following CHD repair could lessen inflammation, reduce
nosocomial infection and improve cardiac function
[11, 13–17, 43–45]. As an inexpensive medication (approxi-
mately $15/month) that is generally regarded as safe,
vitamin D has the potential to be an ideal intervention for
improving outcomes following CHD repair. As protocols
and guidelines should be evidenced-based, well-designed
clinical trials are essential to adjust clinical practice. This
trial aims to determine whether a preoperative proposed
dosing strategy will be sufficient to elevate preoperative
25OHD and prevent postoperative vitamin D deficiency.
Further clinical study will be required to investigate how
normalization of vitamin D levels impacts the clinical
course of patients with CHD requiring cardiac surgery.
Trial status
At the time of writing, 62 % of the target sample size
had been enrolled and the anticipated study completion
date is January 2016.
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